Colorectal cancer liver metastatic tumor targeting antibody and application thereof
By screening and synthesizing TLS-related high-mutation frequency antibodies, the problem of limited benefits of immunotherapy in CRLM is solved, the effect of inhibiting tumor growth in vivo is achieved, and a new immunotherapy strategy for CRLM is provided.
Patent Information
- Application Number
- CN202410885392.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-03
- Publication Date
- 2024-11-08
AI Technical Summary
The existing immunotherapy has limited benefits in colorectal cancer liver metastasis (CRLM) and its clinical significance for the microenvironment and tertiary lymphoid structure (TLS) distribution of metastatic CRC cells in the liver, affecting the therapeutic effect.
Through single-cell multiomic sequencing and patient-derived TLS-related monoclonal antibodies, high mutation frequency and high clonal amplification antibody sequences were synthesized and screened to prepare human-mouse chimeric monoclonal antibodies and whole human antibodies. Antibodies that can bind to tumors and exert anti-tumor functions, such as mAb6, mAb7, mAb9, and mAb10, prove the tumor responsiveness of the in situ antibody production in tumor tissues.
In vitro experiments, antibodies mediate tumor phagocytosis function of macrophages and inhibit tumor growth in humanized mouse models of colorectal cancer, providing a new therapeutic strategy.
Smart Images

Figure CN118909126A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and specifically relates to a colorectal cancer liver metastasis tumor targeting antibody and application thereof. Background Art
[0002] Colorectal cancer (CRC) is the fourth leading cause of cancer-related death worldwide. Colorectal cancer liver metastasis (CRLM) occurs in nearly 50% of CRC patients and accounts for more than 70% of colorectal cancer deaths. Although surgery is a curative treatment for liver metastasis, more than 50% of patients experience recurrence within 2 years. Currently, an increasing number of immunotherapies, such as immune checkpoint blockade (ICB), have rewritten the treatment options for different types of cancer, however, immunotherapy has limited benefits in CRLM. Therefore, in-depth analysis of the metastatic microenvironment may provide new insights into immunotherapy for CRLM.
[0003] Tertiary lymphoid structures (TLS) are ectopic lymphoid follicles composed mainly of myeloid cells, T cells, and B cells. Recent studies have shown that TLS may play a key role by regulating the tumor microenvironment (TME), which is closely associated with good response to immunotherapy and improved overall survival (OS) in various solid tumors, such as melanoma, soft tissue sarcoma, and breast cancer. However, the distribution and composition of TLS vary in different cancers, leading to different clinical outcomes. For example, in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, intratumoral TLS are associated with improved prognosis, while peritumoral TLS indicate a poor prognosis. In CRC, TLS located at the front of tumor invasion indicate better survival. However, some helper T cell-dominated TLS are associated with disease recurrence in patients with stage II or III CRC. Currently, the unique microenvironment encountered by metastatic CRC cells in the liver and the distribution and clinical significance of TLS are still poorly understood. As the main components of TLS, B cells and plasma cells (PC) produce antibodies that are crucial to humoral immunity. Antibodies can play a role through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), complement-dependent cytotoxicity, and enhanced antigen presentation. However, little is known about the formation and biological functions of B cells in CRLM. In this study, we used single-cell multi-omics sequencing, patient-derived TLS-related monoclonal antibodies, and humanized mouse models to study the differences in antibodies associated with TLS in CRLM, synthesized and screened antibodies with anti-tumor function, and provided a new approach for the treatment of colorectal cancer liver metastasis (CRLM). Summary of the invention
[0004] The present invention used paired BCR heavy chains (IgH) and light chains (IgL) derived from tumor-infiltrating TLS-associated PCs to generate a variety of monoclonal antibodies in vitro, screened sequences with high mutation frequencies and high clonal amplification to prepare human-mouse chimeric monoclonal antibodies and fully human antibodies, and finally screened out 4 antibodies that can bind to tumors and exert anti-tumor functions, demonstrating the tumor reactivity of antibodies generated in situ in tumor tissues of CRLM patients.
[0005] Antibody Binding Fragment In one aspect, the present invention provides an antibody binding fragment, wherein the binding fragment is a heavy chain variable region and / or a light chain variable region fragment, wherein the heavy chain variable region amino acid sequence is shown in SEQ ID NO: 1, 5, 9 or 13; the light chain variable region amino acid sequence is shown in SEQ ID NO: 3, 7, 11 or 15; In one embodiment, the amino acid sequence of the heavy chain variable region of the antibody binding fragment is as shown in SEQ ID NO: 1, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO: 3; In one embodiment, the amino acid sequence of the heavy chain variable region of the antibody binding fragment is as shown in SEQ ID NO:5, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO:7; In one embodiment, the amino acid sequence of the heavy chain variable region of the antibody binding fragment is as shown in SEQ ID NO:9, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO:11; In one embodiment, the amino acid sequence of the heavy chain variable region of mAb6 of the antibody binding fragment is shown in SEQ ID NO:13, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:15.
[0006] The term "antibody binding fragment" generally refers to one or more fragments of a full-length antibody that retain the ability to bind to the antibody. In some embodiments, the antibody binding fragment has a sequence of one or more amino acid substitutions, deletions or additions compared to the amino acid sequence provided by the present invention, and substantially retains the biological function derived from the sequence; the one or more amino acids include 1, 2, 3, 4, 5 or 6 amino acid substitutions, deletions or additions. It is clear to those skilled in the art that the structure of a protein can be changed without adversely affecting its activity and functionality, for example, one or more conservative amino acid substitutions can be introduced into the amino acid sequence of a protein without adversely affecting the activity and / or three-dimensional structure of the protein molecule.
[0007] In some embodiments, the amino acid sequence contained in the antibody binding fragment has one or more modification groups. For example, the antibody binding fragment disclosed in the present invention can contain a flexible linker sequence, or can be modified to add a functional group (e.g., PEG, a drug, a toxin, or a label).
[0008] In some embodiments, the antibody binding fragment includes a modified derivative, i.e., modified by covalent attachment of any type of molecule to the antibody binding fragment, wherein the covalent attachment does not prevent the antibody binding fragment from binding to the epitope. Including but not limited to the following examples, the antibody binding fragment can be glycosylated, acetylated, pegylated, phosphorylated, amidated, derivatized by known protecting / blocking groups, proteolytically cleaved, attached to a cellular ligand or other protein, etc. Any of the numerous chemical modifications can be performed by existing techniques, including but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc.
[0009] In some embodiments, the antibody binding fragment can be conjugated to a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a medicament, or PEG. The antibody binding fragment can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent labeled antibody binding fragment is then determined by detecting the luminescence that occurs during the chemical reaction. Examples of chemiluminescent labeled compounds include luminol, isoluminol, aromatic acridinium esters, imidazoles, acridinium salts, or oxalates.
[0010] In some embodiments, the antibody bound to the antibody binding fragment includes a monoclonal antibody, a polyclonal antibody, a bispecific antibody, or a humanized antibody; optionally, the humanized antibody includes a chimeric antibody, a modified antibody, a surface reshaped antibody, or a fully humanized antibody.
[0011] The term "monoclonal antibody (mAb)" refers to antibodies with the same specificity produced by a single B cell clone. Through genetic engineering technology, monoclonal antibodies can be modified to improve their stability, affinity or effector function. Monoclonal antibodies can be transformed into humanized antibodies, which are better tolerated in the human body.
[0012] The term "polyclonal antibodies (pAbs)" refers to a mixture of antibodies produced by multiple B cell clones that respond to different epitopes of the same antigen.
[0013] The term "bispecific antibodies (BsAb)" usually refers to artificial proteins that can bind to two different types of antigens at the same time. They contain two different antigen-binding domains, which do not exist in nature and can only be prepared artificially. The preparation of bispecific antibodies is initially obtained by preparing two different, purified monoclonal antibodies through existing technologies such as chemical coupling, genetic engineering and other methods.
[0014] The term "humanization" refers to: antibodies interact with target antigens primarily through amino acid residues that are located in six heavy and light chain complementary determining regions (CDRs). For this reason, the amino acid sequence inside the CDR between each antibody is more diverse than the sequence outside the CDR. Because the CDR sequence is responsible for most of the antibody-antigen interactions, it is possible to express recombinant antibodies that simulate the properties of specific naturally occurring antibodies by constructing an expression vector, which includes CDR sequences of specific naturally occurring antibodies grafted to framework sequences from different antibodies with different properties. Such framework sequences can be obtained from public DNA databases including germline antibody gene sequences. These germline sequences will be different from mature antibody gene sequences because they do not include fully assembled variable genes, which are formed by V (D) J connections during B cell maturation.
[0015] In some embodiments, based on the fact that the constant region portion of the antibody (i.e., CH and CL regions) or all of the antibody is encoded by human antibody genes, the humanized antibodies include chimeric antibodies, modified antibodies, surface reshaped antibodies or fully humanized antibodies under different preparation processes.
[0016] The term "chimeric antibodies" refers to the use of DNA recombination technology to insert the light and heavy chain variable region genes of heterologous monoclonal antibodies into an expression vector containing the constant region of an antibody from another species, and transform mammalian cells to express chimeric antibodies.
[0017] The term "modified antibody" is also called CDR grafted antibody. The CDR of the antibody variable region is the region where the antibody recognizes and binds to the antigen, which directly determines the specificity of the antibody. The CDR of the mouse monoclonal antibody is transplanted to the variable region of the human antibody to replace the human antibody CDR, so that the human antibody obtains the antigen binding specificity of the mouse monoclonal antibody and reduces its heterology.
[0018] The term "Surface Reshaping Antibodies" refers to the humanization of amino acid residues on the surface of heterologous antibodies. The principle of this method is to replace only the regions that are significantly different from the SAR (Structure-Activity Relationship) of human antibodies, and to select amino acid replacements similar to the surface residues of human antibodies on the basis of maintaining antibody activity and reducing heterology.
[0019] The term "fully humanized antibodies" means that all human antibody genes encoding human antibodies are transferred to genetically engineered antibody gene-deficient animals through transgenic or chromosome transfer technology, so that the animals express human antibodies and achieve the purpose of fully humanized antibodies.
[0020] In some embodiments, the present invention provides a humanized antibody, comprising a constant region (C region) and a variable region (V region), wherein the variable region comprises a heavy chain variable region (VH) and a light chain variable region (VL), In one embodiment, the heavy chain variable region amino acid sequence of the antibody is as shown in SEQ ID NO: 1, and the light chain variable region amino acid sequence is as shown in SEQ ID NO: 3; In one embodiment, the heavy chain variable region amino acid sequence of the antibody is as shown in SEQ ID NO:5, and the light chain variable region amino acid sequence is as shown in SEQ ID NO:7; In one embodiment, the heavy chain variable region amino acid sequence of the antibody is as shown in SEQ ID NO:9, and the light chain variable region amino acid sequence is as shown in SEQ ID NO:11; In one embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:13, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:15.
[0021] In one embodiment, the constant region comprises a constant region of human or murine origin.
[0022] Polynucleotide In another aspect, the present invention provides a polynucleotide encoding the antibody binding fragment.
[0023] In some embodiments, the heavy chain variable region polynucleotide sequence is shown as SEQ ID NO:2, 6, 10 or 14; the light chain variable region polynucleotide sequence is shown as SEQ ID NO:4, 8, 12 or 16.
[0024] In one embodiment, the polynucleotide heavy chain variable region polynucleotide sequence encoding the binding fragment is as shown in SEQ ID NO: 2, and the light chain variable region polynucleotide sequence is as shown in SEQ ID NO: 4; In one embodiment, the polynucleotide heavy chain variable region polynucleotide sequence encoding the binding fragment is as shown in SEQ ID NO:6, and the light chain variable region polynucleotide sequence is as shown in SEQ ID NO:8; In one embodiment, the polynucleotide heavy chain variable region polynucleotide sequence encoding the binding fragment is as shown in SEQ ID NO: 10, and the light chain variable region polynucleotide sequence is as shown in SEQ ID NO: 12; In one embodiment, the polynucleotide heavy chain variable region polynucleotide sequence encoding the binding fragment is as shown in SEQ ID NO: 14, and the light chain variable region polynucleotide sequence is as shown in SEQ ID NO: 16; The polynucleotide sequence has at least 90% sequence identity, for example, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the sequence shown in SEQ ID No. 2, 4, 6, 8, 10, 12, 14, or 16. In some embodiments, the polynucleotide sequence has a sequence with one or more base substitutions, deletions, or additions (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 base substitutions, deletions, or additions) compared to the sequence shown in SEQ ID No. 2, 4, 6, 8, 10, 12, 14, or 16.
[0025] It is clear to those skilled in the art that, based on the degeneracy in the genetic code, most amino acids are encoded by multiple different codons. The genetic code is the process of translating the genetic information on DNA or mRNA into proteins in an organism, wherein each amino acid is encoded by one or more specific three nucleic acid sequences (codons). Based on this property, different nucleic acid sequences (codons) can be transcribed and translated into the same amino acid. As long as the change in the polynucleotide sequence does not result in translation into different amino acids or inactivation of the biological activity of the protein, the polynucleotide sequence falls within the scope of the present invention.
[0026] Composition In another aspect, the present invention provides a composition comprising the antibody binding fragment, or the antibody, or the polynucleotide, and a pharmaceutically acceptable carrier; In some embodiments, the vector includes a cloning vector, an expression vector, a shuttle vector, and an integration vector, which are known to those skilled in the art and may be naturally occurring or artificially synthesized vector structures; in some specific embodiments, the vector is selected from plasmids, bacteriophages, transposons, cosmids, chromosomes, viruses, viral particles, etc., which can replicate when associated with appropriate control elements, and can transfer gene sequences to cells, such as the vector is selected from phage display vectors: using phages as vectors, inserting antibody variable region genes into phage coat protein genes, so that antibody fragments are displayed on the phage surface; yeast display vectors: using yeast surface display technology, the antibody variable region genes are fused with yeast cell wall proteins and displayed on the yeast cell surface; ribosome display vectors: using ribosome display technology, the antibody variable region genes are combined with ribosomal RNA to form mRNA-protein-ribosome complexes, etc.
[0027] In one embodiment, the present invention provides an expression vector comprising the polynucleotide; in some embodiments, it further comprises a regulatory element operably linked thereto, such as an enhancer, a promoter, a terminator, a marker gene or a reporter gene.
[0028] In some embodiments, the present invention provides a host cell comprising the expression vector, which is used to clone the antibody variable region gene into a vector suitable for expression in the host cell, such as a plasmid or a viral vector, to produce a recombinant antibody or a fragment thereof.
[0029] Immunoconjugates The present invention provides an immunoconjugate comprising the antibody binding fragment, or the antibody, or the polynucleotide, wherein the antibody binding fragment, antibody or polynucleotide is connected to a therapeutic agent. In some embodiments, the therapeutic agent is a drug, a cytotoxin or a radioactive isotope. In a specific embodiment, the immunoconjugate is an antibody-drug conjugate (ADCs), which is composed of a monoclonal antibody, a drug (cytotoxic payload) and a linker.
[0030] The term "immunoconjugates" refers to a class of complexes that link biologically active molecules to antibodies. This coupling can enhance the targeting of drugs, allowing them to act more precisely on specific cells or tissues.
[0031] Chimeric Antigen Receptor (CAR) The present invention provides a chimeric antigen receptor (CAR), whose antigen recognition region contains the binding fragment or the polynucleotide. In some embodiments, the present invention provides an immunocompetent cell expressing the CAR; preferably, the immunocompetent cell is a CAR-T or CAR-NK cell.
[0032] The term "chimeric antigen receptor (CAR)" is a synthetic receptor, which is commonly used in engineered T cell therapy (also known as CAR-T therapy) and CAR-NK cell therapy in some embodiments. The CAR structure includes an antigen recognition region: usually derived from the variable region of a monoclonal antibody to form a scFv (single-chain antibody fragment), which can specifically recognize antigens on the surface of cancer cells; a transmembrane region: connecting the antigen recognition region and the intracellular signaling region of the CAR, usually derived from the natural receptor of immune cells; a co-stimulatory signaling region: providing the necessary second signal to enhance the activation and proliferation of T cells. Common co-stimulatory molecules include CD28, 4-1BB (CD137), OX40 (CD134), etc.; an activation region: usually derived from the ζ chain of the T cell receptor (TCR), responsible for transmitting activation signals; an intracellular signaling region: involved in the activation, proliferation and cytokine production of T cells.
[0033] In some embodiments, the present invention provides a pharmaceutical composition comprising the antibody, or the immunoconjugate, or the immunocompetent cell. The antibody, immunoconjugate or immunocompetent cell provided by the present invention can be administered in combination with other drugs, such as chemotherapy drugs (fluorouracil, oxaliplatin, raltitrexed, folinic acid or irinotecan, etc.), targeted therapy drugs (cetuximab, bevacizumab, etc.) or immunotherapy drugs (such as PD-1 / PD-L1 inhibitors, etc.).
[0034] In one embodiment, the present invention provides a kit comprising the antibody binding fragment, or the antibody, or the polynucleotide, or the expression vector, or the host cell, or the composition, or the immunoconjugate, or the chimeric antigen receptor, or the immunocompetent cell, or the pharmaceutical composition.
[0035] application In some embodiments, the antibody binding fragment, the antibody, the polynucleotide, the expression vector, the host cell, the composition, the immunoconjugate, the chimeric antigen receptor, the immunocompetent cell, the pharmaceutical composition, or the kit of the present invention are used in the preparation of a drug for treating a disease, preferably, the disease is colorectal cancer or colorectal liver metastasis.
[0036] The technical effects achieved by the present invention are: In the present study, single-cell RNA sequencing and spatial enhanced resolution omics sequencing (Stereo-seq) were used to find that TLS+ tumors were rich in IgG+ plasma cells (PC), while TLS- tumors were rich in IgA+ PC. By synthesizing monoclonal antibodies derived from TLS-related PCs in vitro, it was found that TLS-related PCs can secrete tumor-targeting antibodies. Further, we screened 20 sequences with high mutation frequencies and high clonal amplification for antibody synthesis, and finally screened out 4 antibodies mAb6, mAb7, mAb9, and mAb10 that can bind to tumors and exert anti-tumor functions. We demonstrated in vitro experiments that antibodies mAb6, mAb7, mAb9, and mAb10 mediate the function of macrophages to phagocytose tumors, and demonstrated the anti-tumor activity of antibody mAb6 in humanized mice with human colorectal cancer.
[0037] The present invention demonstrates that tumor-targeting IgG antibodies produced in situ by tumor-infiltrating PCs promote tumor killing in vitro and inhibit tumor growth in humanized mice with human colorectal cancer in vivo. The present invention further explores tumor TLS-derived monoclonal antibodies to provide a reference for the development of new immunotherapy strategies for cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 Schematic diagram of the structures of human-mouse chimeric antibodies and fully human antibodies containing the same variable region functional fragments according to the present invention.
[0039] Figure 2 Figure 1 shows the immunofluorescence binding of the chimeric antibody containing the variable region functional fragment in the tissue sections of patients with colorectal cancer. (A) Representative immunofluorescence staining of the mAb6 chimeric antibody in the tumors of three patients with colorectal cancer liver metastasis, P2938, P2864, and P2810, and the normal liver adjacent to the tumor, with a scale of 50 μm; (B) All 20 chimeric antibodies recognized CK20 in the tumors of the three patients. + Proportion of tumors; (CE) Proportion of immunofluorescence staining positive areas of all 20 human-mouse chimeric antibodies in tumors and adjacent areas of three patients. Error bars represent mean ± SD; unpaired t-test was used to compare the two groups, ns means no statistical difference, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
[0040] Figure 3Figures showing the binding of human-mouse chimeric antibodies containing variable region functional fragments in tumors and liver cell lines of the present invention. (A) Flow cytometry detection of the binding of 20 human-mouse chimeric antibodies in human colon cancer cell lines HCT116, HT29 and liver cell line MIHA. If the average fluorescence intensity of the three repeated experiments of the antibody is more than 1.5 times higher than the isotype, it is marked in red; (BC) Representative graphs and quantitative analysis of the binding of 20 human-mouse chimeric antibodies in human colon cancer cell lines HCT116, HT29 and liver cell line MIHA by immunofluorescence detection. The scale bar is 10 μm; the error bar represents the mean ± standard deviation; each antibody is compared with the isotype using an unpaired t-test, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
[0041] Figure 4 The ability of fully human antibodies containing variable region functional fragments in mediating macrophage phagocytosis of tumor cells. (A) The phagocytic ratio of human THP-1 cells to HCT116 cells when fully human antibodies mAb2 / 3 / 5 / 7 / 9 / 10, isotype control, and no antibody were added; (B) The phagocytic ratio of human THP-1 cells to HT29 cells when fully human antibodies mAb2 / 3 / 5 / 7 / 9 / 10, isotype control, and no antibody (noAb) were added. The statistical test between groups was compared with the no Ab group using an unpaired t-test, * p<0.05, ** p<0.01, **** p<0.0001.
[0042] Figure 5 The therapeutic effect of the fully human antibody mAb6 in the humanized colorectal cancer mouse model. (A) Growth curve of subcutaneous tumors of humanized mouse HCT116 colorectal cancer. The mice were randomly divided into three groups and treated with 200ug mAb6, 200ug Isotype control or the same volume of PBS. The drug was administered from 1 week after tumor transplantation, once every 3 days, for a total of 5 times, and the experiment was terminated 3 weeks after tumor transplantation. The two-way ANOVA test was used for inter-group comparison, ns no statistical difference, **** p<0.0001; (B) Tumor photos of subcutaneous tumors of humanized mouse HCT116 colorectal cancer at week 3, and quantitative comparison of tumor volume. The one-way ANOVA test was used for inter-group comparison, ns no statistical difference, * p<0.05, *** p<0.001. Specific embodiments
[0043] The technical scheme of the present invention is described in detail below in conjunction with the accompanying drawings and Examples, but the present invention is not therefore limited to the scope of the embodiments described. Unless otherwise specified, the experiments and methods described in the embodiments are carried out substantially according to conventional methods well known in the art and described in various references, and the reagents and raw materials used in the present invention are all commercially available. If specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer is not specified in the reagents or instruments used, they are all conventional products that can be obtained commercially. Those skilled in the art will appreciate that the embodiments describe the present invention by way of example and cannot limit the scope of the invention claimed for protection. All public cases and other references mentioned herein are incorporated herein by reference in their entirety.
[0044] Example 1 1. Acquisition of variable regions of tumor-associated antibodies against colorectal cancer liver metastases Using 10X's 5' single-cell sequencing technology, V(D)J sequencing was performed on B cells and plasma cells in colorectal cancer liver metastases to obtain the variable region sequences of each cell's light chain and heavy chain. Sequences with high mutation frequency and high clonal amplification were screened for 20 antibody synthesis, and finally 4 antibodies mAb6, mAb7, mAb9, and mAb10 that can bind to tumors and exert anti-tumor functions were screened. The variable region sequence information of the antibodies is shown in Table 1: Table 1 Antibody variable region sequence information
[0045] 2. Antibody preparation See also Figure 1 , the variable region sequences of the paired heavy chain (IgH) and light chain (IgL) were inserted into an expression plasmid with the antibody constant region (plasmid purchase source: Genscript Biotech Corporation). To construct recombinant human-mouse chimeric antibodies, constructs containing human heavy and light chain variable regions were cloned into mouse IgG2a and IgK expression vectors pcDNA3.4. The recombinant plasmids encoding the target proteins were then transiently co-transfected into CHO cells (source: Genscript Biotech). The recombinant antibodies were purified from the supernatant of the cultured cells. Finally, the purified antibodies were analyzed by SDS-PAGE and HPLC to measure their molecular weight and purity. To generate recombinant mAbs with a fully human Fc fragment (fully human antibodies), the same human heavy and light chain variable region sequences were cloned into a human IgG1 expression vector, transfected into HEK293 cell culture, and operated according to similar expression and purification protocols.
[0046] 3. Anti-CRLM antibody affinity test for patient tumor tissue Fresh tumor and adjacent liver tissues from three patients with CRLM were collected, embedded in OCT and stored at -80°C. The frozen tissues were cut into 10 µm thick sections and stained using the four human-mouse chimeric monoclonal antibodies synthesized above. The staining experiment used human-mouse chimeric monoclonal antibodies (25 μg / ml) and rabbit anti-human CK20 (Abcam, ab76126) as primary antibodies, Cy3-labeled anti-mouse IgG (Jackson, 715-165-150) and Alexa Fluor 488-labeled anti-rabbit IgG (Cell Signaling Technology, 4412) as secondary antibodies, and DAPI (Abcam, ab104139) for nucleic acid staining. No primary antibody was added to the negative control group during the staining process. Images of the stained sections were acquired using a confocal laser scanning microscope (Olympus FV3000, Japan). All images were analyzed using ImageJ software. See Figure 2 It can be observed that the binding signals of mAb6 / 7 / 9 / 10 in all or part of the patient's tumor were higher than those in the adjacent tumor.
[0047] 4. Affinity testing of anti-CRLM antibodies against patient tumor cell lines We used flow cytometry and immunofluorescence to detect the affinity of antibodies for tumor cells.
[0048] Flow cytometry: Colorectal cancer cell lines (HCT116 and HT29) and hepatocyte cell line (MIHA) cells were digested and resuspended, and 1x10 5 The cells were incubated with 50 μg / ml mAbs or 50 μg / ml anti-HEL control antibody at room temperature for 30 minutes, washed with flow buffer, and then incubated with Alexa Fluor 647-anti-mouse IgG secondary antibody at room temperature for 30 minutes. After washing, the cells were fixed with 1% formalin, scanned using a flow cytometer (BD FACS LSRFortessa X-20) and the data were analyzed using FlowJo10.8 software. Figure 3 A, Flow cytometry showed that mAb3 / 6 / 7 / 9 could significantly recognize tumor cell lines, but not or only weakly recognize liver cell lines.
[0049] Immunofluorescence: The colorectal cancer cell lines HCT116 and HT29 and the liver cell line MIHA in the logarithmic growth phase were digested and resuspended in DMEM medium and counted. 5x10 5Cells were plated on slides in 24-well plates and cultured overnight. After attachment, cells were fixed with 4% formaldehyde, washed with PBS, permeabilized with Triton X-100, and blocked with 5% goat serum. Then, mAbs or HEL mouse IgG2A-Kappa isotype control (Abinvivo, B115101) at a concentration of 25 μg / ml were added for staining, and the slides were incubated at 4°C overnight. After overnight incubation, the slides were washed and incubated with FITC-labeled anti-mouse IgG (Thermo Fisher Scientific, F-2761) for 1 hour at room temperature, and finally, nuclei were stained with DAPI. Images of stained sections were acquired using a confocal laser scanning microscope (Olympus FV3000, Japan). All images were analyzed using ImageJ software. See. Figure 3 BC, Immunofluorescence confirmed the high binding of mAb6 / 7 / 9 / 10 to tumor cells. Because tumor cells have great heterogeneity, although mAb10 failed to bind to three patient tissues, it could recognize two colorectal cancer cell lines, suggesting that mAb10 also has tumor binding ability.
[0050] 5. In vitro tumor phagocytosis assay with anti-CRLM antibodies Antibody-dependent cellular phagocytosis (ADCP) assay was performed by flow cytometry: THP-1 cells were cultured for 24 hours with 100 ng / ml palmityl 12-myristate propionate (PMA, Sigma-Aldrich, P8139) to stimulate differentiation into macrophages and then stained with CFSE (Thermo Fisher Scientific, C34570). HCT116 or HT29 tumor cells were labeled with Celltracker Red CMTPX dye (Thermo Fisher Scientific, C34552). 5x104 labeled THP-1 cells and 1x105 tumor cells were mixed in 100 μl of culture medium and added to a 96-well ultra-low attachment round bottom plate (Corning, 7007). The fully human monoclonal antibodies synthesized in this study were diluted in 100 μl of culture medium at a concentration of 10 μg / ml and added to the co-culture system. The cells were centrifuged at 700 rpm for 1 minute to aggregate the cells at the bottom of the wells and then incubated for 6 hours at 37°C, 5% CO2. After incubation, the cells were analyzed using flow cytometry (BD FACSLSRFortessa X-20). Phagocytosis was determined by the percentage of PE-CF594+CFSE+ cells among all CFSE+ macrophages. Figure 4Experiments have shown that mAb6 / 7 / 9 significantly promotes the phagocytosis of HCT116 colorectal cancer tumor cells by macrophages, and mAb6 / 7 / 9 / 10 can significantly promote the phagocytosis of HT29 colorectal cancer tumor cells by macrophages.
[0051] 6. In vivo tumor killing experiment with anti-CRLM antibody Establishment of humanized mouse model: 15-16-week-old NCG-M humanized mice were constructed by Jiangsu GemPharmatech Co., Ltd. NCG-M mice were genetically modified to produce human granulocyte / macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3) and stem cell factor (SCF) in severely immunodeficient NCG mice (NOD-Prkdcem26Cd52Il2rgem26Cd22 / NjuCrl, NCG), thereby developing human immune cells (including T / B cells and myeloid cells) in mice. After 3-4-week-old NCG-M mice received sublethal whole-body irradiation, human CD34+ hematopoietic stem cells (HSCs) were transplanted by intravenous injection. Peripheral blood was collected 8 weeks after transplantation to confirm the successful reconstruction of human immune cells by flow cytometry.
[0052] Establishment of humanized colorectal cancer model: HCT116 in logarithmic growth phase was resuspended in PBS and 3x10 5 The cells were injected subcutaneously in the armpit of mice, which was recorded as experimental day 0. The long and short diameters of the subcutaneous tumors were monitored twice a week.
[0053] On the 7th day after tumor transplantation, the mice with transplanted tumors were divided into 3 groups, 5 mice in each group, and received treatment with mAb6 fully human antibody (200μg / mouse), human IgG1 isotype control (Abinvivo, B117901, 200μg / mouse), and PBS control treatment (200μl / mouse), respectively. The drugs were administered once every 3 days for a total of 2 weeks. The experiment was terminated on the 21st day, and the tumor tissue was measured and weighed. Figure 5 , and found that mAb6 could significantly inhibit tumor growth compared with the two controls.
Claims
1. An antibody binding fragment, characterized in that The binding fragment is a heavy chain variable region and / or a light chain variable region fragment, the heavy chain variable region amino acid sequence is shown in SEQ ID NO: 1, 5, 9 or 13; the light chain variable region amino acid sequence is shown in SEQ ID NO: 3, 7, 11 or 15.
2. The antibody binding fragment according to claim 1, characterized in that The antibody includes a monoclonal antibody, a polyclonal antibody, a bispecific antibody or a humanized antibody; optionally, the humanized antibody includes a chimeric antibody, a modified antibody, a surface reshaped antibody or a fully humanized antibody.
3. An antibody comprising a constant region and a variable region, wherein the variable region comprises a heavy chain variable region and a light chain variable region, wherein: The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO: 1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 3; or the heavy chain variable region amino acid sequence of the antibody is as shown in SEQ ID NO:5, and the light chain variable region amino acid sequence is as shown in SEQ ID NO:7; or the heavy chain variable region amino acid sequence of the antibody is as shown in SEQ ID NO:9, and the light chain variable region amino acid sequence is as shown in SEQ ID NO:11; Or the heavy chain variable region amino acid sequence of the antibody is as shown in SEQ ID NO:13, and the light chain variable region amino acid sequence is as shown in SEQ ID NO:
15.
4. The antibody according to claim 3, characterized in that The constant region includes a constant region of human or mouse origin.
5. A polynucleotide encoding the antibody binding fragment of claim 1 or 2.
6. The polynucleotide according to claim 5, characterized in that The heavy chain variable region polynucleotide sequence is shown as SEQ ID NO: 2, 6, 10 or 14; the light chain variable region polynucleotide sequence is shown as SEQ ID NO: 4, 8, 12 or 16.
7. An expression vector, characterized in that: Containing the polynucleotide according to claim 5 or 6.
8. A host cell, characterized in that Containing the expression vector according to claim 7.
9. A composition, characterized in that It comprises the antibody binding fragment of claim 1 or 2, the antibody of claim 3 or 4, or the polynucleotide of claim 5 or 6, and a pharmaceutically acceptable carrier.
10. An immunoconjugate, characterized in that: The invention comprises the antibody binding fragment of claim 1 or 2, or the antibody of claim 3 or 4, or the polynucleotide of claim 5 or 6, wherein the antibody binding fragment, antibody or polynucleotide is linked to a therapeutic agent.
11. The immunoconjugate according to claim 10, characterized in that Therapeutic agents include drugs, cytotoxins, or radioisotopes.
12. A chimeric antigen receptor (CAR), characterized in that Its antigen recognition region contains the binding fragment described in claim 1, or the polynucleotide described in claim 5 or 6.
13. An immunocompetent cell, characterized in that: The cells express the CAR of claim 12; preferably, the immunocompetent cells are CAR-T or CAR-NK cells.
14. A pharmaceutical composition, characterized in that Containing the antibody according to claim 3 or 4, or the immunoconjugate according to claim 10 or 11, or the immunocompetent cell according to claim 13.
15. A kit, characterized in that: The kit comprises the antibody binding fragment of claim 1 or 2, or the antibody of claim 3 or 4, or the polynucleotide of claim 5 or 6, or the expression vector of claim 7, or the host cell of claim 8, or the composition of claim 9, or the immunoconjugate of claim 10 or 11, or the chimeric antigen receptor of claim 12, or the immunocompetent cell of claim 13, or the pharmaceutical composition of claim 14.
16. Use of the antibody binding fragment of claim 1 or 2, or the antibody of claim 3 or 4, or the polynucleotide of claim 5 or 6, or the expression vector of claim 7, or the host cell of claim 8, or the composition of claim 9, or the immunoconjugate of claim 10 or 11, or the chimeric antigen receptor of claim 12, or the immunocompetent cell of claim 13, or the pharmaceutical composition of claim 14, or the kit of claim 15 in the preparation of a drug for treating a disease, preferably, the disease is colorectal cancer or colorectal liver metastasis.
